Tafasitamab plus lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) improved progression-free survival (PFS) compared with R-CHOP alone and had manageable safety for patients with aggressive B-cell lymphomas in the phase 3 frontMIND study, according to a presentation at the 2026 ASCO Annual Meeting.
The frontMIND trial enrolled patients with newly diagnosed, high-intermediate or high risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma. In the overall population of 899 patients, after a median follow-up of 35.2 months, Tafa-Len-R-CHOP significantly improved PFS compared with R-CHOP (hazard ratio [HR], 0.75; 95% CI, 0.59-0.96; P=.019). Tafa-Len-R-CHOP also improved PFS outcomes versus R-CHOP in the subset of 773 patients with centrally confirmed lymphoma subtypes with 24-month PFS rates of 72.7% versus 62.2% (HR, 0.68; 95% CI, 0.52-0.88), respectively. An interim overall survival analysis favored Tafa-Len-R-CHOP with a HR of 0.85.
Any-grade treatment-emergent adverse events occurred in 98.6% of the Tafa-Len-R-CHOP arm versus 97.1% of the R-CHOP arm. Grade 3 or higher TEAEs occurred in 86.7% of the Tafa-Len-R-CHOP arm versus 76.1% of the R-CHOP arm. Discontinuation due to TEAEs occurred in 25.7% of the Tafa-Len-R-CHOP arm versus 17.9% of the R-CHOP arm. Deaths due to TEAEs occurred in 5.9% of the Tafa-Len-R-CHOP arm versus 3.8% of the R-CHOP arm, however, there were fewer deaths overall with Tafa-Len-R-CHOP (18.5%) compared with R-CHOP (21.7%).
Tafa-Len-R-CHOP represents a potential new first-line standard of care for patients with high-risk DLBCL or high-grade B-cell lymphoma, regardless of cell of origin subtype, said first author Georg Lenz, MD, PhD, of University Hospital Münster in Germany.
Leave feedback about this